Advanced Biomed (ADVB) EBITDA (2023 - 2026)

Advanced Biomed has disclosed EBITDA across 4 years of filings, most recently posting -$519905.0 for Q1 2026.

• EBITDA for Q1 2026 came in at -$519905.0, up 61.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (up 258.53% YoY), and the FY2025 annual result was -$3.0 million, down 23.45% from the prior year.
• EBITDA came in at -$519905.0 for Q1 2026 at Advanced Biomed, down from $6.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $6.5 million in Q4 2025 to a low of -$1.3 million in Q1 2025.
• The 4-year median for EBITDA is -$588865.5 (2023), against an average of $48104.0.
• Peak annual rise in EBITDA reached 1464.27% in 2025, while the deepest fall reached 93.51% in 2025.
• Advanced Biomed's EBITDA stood at -$608303.0 in 2023, then rose by 21.95% to -$474798.0 in 2024, then surged by 1464.27% to $6.5 million in 2025, then plunged by 108.03% to -$519905.0 in 2026.
• The last three EBITDA figures came in at -$519905.0 (Q1 2026), $6.5 million (Q4 2025), and -$473440.0 (Q3 2025), per Business Quant data.